Feature | February 06, 2013 | Dave Fornell

Sunshine Rule Increases Transparency in Healthcare

Affordable Care Act provision calls for vendors to disclose all financial connections physicians have with their companies

Sunshine act, disclosure, cardiology, radiology

The Centers for Medicare and Medicaid Services (CMS) announced a final rule Feb. 1, 2013, that will increase public disclosure of financial relationships between drug and device manufacturers and physicians and teaching hospitals. Called the “National Physician Payment Transparency Program: Open Payments,” this is one of many steps in the Affordable Care Act designed to create greater transparency in the healthcare market.


This increased transparency is intended to help reduce the potential for conflicts of interest that physicians or teaching hospitals could face as a result of their relationships with manufacturers.
 
“You should know when your doctor has a financial relationship with the companies that manufacture or supply the medicines or medical devices you may need,” said Peter Budetti, M.D., CMS deputy administrator for program integrity. “Disclosure of these relationships allows patients to have more informed discussions with their doctors.”
 
This rule finalizes the provisions that require manufacturers of drugs, devices, biologicals and medical supplies covered by Medicare, Medicaid or the Children’s Health Insurance Program (CHIP) to report payments or other transfers of value they make to physicians and teaching hospitals to CMS. CMS will post that data to a public website. The final rule also requires manufacturers and group purchasing organizations (GPOs) to disclose to CMS physician ownership or investment interests. 
 
Support for the law was voiced by vendors in a statement from the Medical Imaging and Technology Alliance (MITA), an industry group of medical imaging equipment, radiation therapy and radiopharmaceutical manufacturers and product developers. “MITA and our member companies have long supported the Sunshine Act and commend CMS for issuing the final regulations,” MITA said. “We appreciate that CMS has given device manufacturers 180 days after publication to implement the final regulations, so that our members have sufficient time to successfully implement the law. MITA looks forward to conducting a thorough review of the rule, so we are able to help our members fully understand the provisions.”
 
This new reporting will apply to applicable manufacturers and GPOs. These organizations, as well as the physicians and teaching hospitals, will have an opportunity to review and correct reported information prior to its publication. 
 
In order to give applicable manufacturers and applicable GPOs sufficient time to prepare, data collection will begin on Aug. 1, 2013. Applicable manufacturers and applicable GPOs will report the data for August through December of 2013 to CMS by March 31, 2014, and CMS will release the data on a public website by Sept. 30, 2014. CMS is developing an electronic system to facilitate the reporting process.
 
This type of disclosure is not new in devices-intensive specialties such as cardiology, as public disclosures are already required as part of their publication in most peer review journals and at scientific meetings. At the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting, all speakers in sessions are required to show a slide of their financial connections with vendors for 10 seconds prior to beginning their discussions.
 
Origins of the Sunshine Act
 
Sen. Chuck Grassley (R-Iowa) is the co-author of the bipartisan Sunshine Act, which was enacted in March 2010, but the final rules for its implementation were only announced Feb. 1. The legislation came after Grassley’s investigative and oversight work that exposed numerous questionable financial relationships between drug companies and doctors. For example, at Stanford University, the chairman of psychiatry received a federal grant to study a drug, while partially owning as much as $6 million in stock in a company that was seeking federal approval of that drug. After exposure, the federal government removed the individual from the grant. 
 
“Disclosure brings about accountability and accountability will strengthen the credibility of medical research, the marketing of ideas and, ultimately, the practice of medicine,” Grassley said in a statement this week. “The lack of transparency regarding payments made by the pharmaceutical and medical device community to physicians has created a culture that this law should begin to change substantially. The reform represented by the Grassley-Kohl Sunshine Law is in patients’ best interests. The goal is straightforward and CMS needs to make certain the reporting and disclosure are complete and clear.”?
 
More Than Half of Physicians are Unprepared
 
While the disclosures now required in the Sunshine Act may by commonplace in some specialties, it is not in others, where it will be a major change from previous practice. Global technology security company MMIS this week announced the results of its third annual survey of more than 1,000 doctors and their knowledge of the Sunshine Act. It found that physicians are actually less informed than they were one year ago.
 
The survey revealed more than half of surveyed physicians admitted they did not know that the law requires pharmaceutical and medical device companies to report on expenditures annually, and that such information would be available in a publicly searchable database. It showed 63 percent were deeply concerned that a record of these payments will be available in a publicly searchable database.
 
Additional survey findings disclose that 21 percent of physicians would sever their relationship with a manufacturer who reported inaccurate information about payments or transfers of value if disclosed to the public, and 43 percent admitted this would affect their ongoing relationship with industry. The survey also included written physician comments and concerns; these ranged from loss of privacy to a lack of awareness on the part of the general public as to the context of physician/industry relationships.
 
"There are approximately 3,000 manufacturers of drugs and devices providing valuable education and resources to physicians that enhance patient care. Increasing transparency of the relationship between industry and our healthcare providers will undoubtedly encourage scrutiny by the public, physician peers and their institutions," said CEO of MMIS, Michaeline Daboul. "Government, industry and physician organizations will need to increase communication in this new age of transparency, share data prior to public dissemination and provide a process for physicians and institutions to resolve disputes regarding incorrect or inaccurate information."
 
According to the survey, 54 percent of physicians who had industry relationships received samples, 57 percent received food or beverages in the workplace, 48 percent participated in a medical industry sponsored program, 11 percent participated in speaker bureau programs, 10 percent participated in advisory board programs and most surprisingly, 2 percent are still accepting free event tickets or gifts.
 
MMIS, Inc. conducts this study annually to understand physician awareness and attitudes as they relate to the Sunshine Act. The study was conducted by The Regulatory Law Group PLLC, using Healthcare Data Solutions' database of physicians, between Jan. 17-18, 2013.
 
The final rule can be downloaded at: www.federalregister.gov/public-inspection  

 


 


Related Content

Guerbet, acquisition, Mallinckrodt, CMDS business, contrast media, CT, MRI
News | Contrast Media| July 29, 2015
Guerbet announced that it has entered into a definitive agreement under which it will acquire Mallinckrodt's contrast...
Vital Images, Toshiba, CT Myocardial Perfusion, cardiac CT, CORE 320 study
Technology | July 15, 2015
Vital Images Inc. will debut its U.S. Food and Drug Administration (FDA) 510(k)-cleared CT Myocardial Perfusion...
SHAPE, coronary artery calcium, USPSTF, heart attack risk
News | Computed Tomography (CT)| July 08, 2015
The Society for Heart Attack Prevention and Eradication (SHAPE) submitted a letter to the U.S. Preventive Services Task...
Toshiba CT

PinnacleHealth selected Toshiba as its imaging systems vendor because of its quality and to help reduce imaging radiation dose to improve patient safety.

Sponsored Content | Case Study | Radiation Dose Management| July 07, 2015
Safety accidents drive up costs, damage reputations and lower patient satisfaction scores. For instance, if a patient...
osteoporosis, heart disease, linked, older people, Southampton MRC, CT
News | Cardiac Diagnostics| July 02, 2015
University of Southampton scientists have discovered a link between coronary heart disease and osteoporosis, suggesting...
radiation exposure, CT, X-ray, cancer, James Welsh, Jeffry Siegel, Loyola
Feature | Radiation Dose Management| July 01, 2015
In recent years, there has been widespread media coverage of studies purporting to show that radiation from X-rays,...
Siemens, MES contract, William Osler Health System, Ontario, Canada
News | Cardiac Imaging| June 26, 2015
Canadian hospital William Osler Health System (Osler), based in Ontario, has awarded Siemens Healthcare a Managed...
CT System
News | Advanced Visualization| June 24, 2015
Texas Children's Hospital successfully separated Knatalye Hope and Adeline Faith Mata in late February, completing one...
News | Business| June 18, 2015
IMRIS Inc. received a letter May 26 from the NASDAQ Stock Market stating that it would be delisted and trading...
Toshiba, Aquilion ONE, enhancements, FDA, patient safety
Technology | June 18, 2015
Toshiba America Medical Systems Inc. has received U.S. Food and Drug Administration (FDA) clearance for detector and...
Overlay Init